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(or hyperfluorescein spots) observed on postop-
erative fluorescein angiography were located at 
the preoperative trunk of a sea-fan–shaped vascu-
lar network of polypoidal choroidal vasculopathy 
(Fig. S1A in the Supplementary Appendix, avail-
able with the full text of this letter at NEJM.org), 
and because these hyperfluorescein spots seemed 
to indicate pooling rather than leakage, we inter-
preted them as an abnormal vessel structure that 
remained at the trunk after the removal of cho-
roidal neovascularization. The preoperative opti-
cal coherence tomographic images also showed a 
trunk-like vessel with accompanying network 
vessels, some part of which remained, as shown 
on the optical coherence tomographic image ob-
tained 3 days after transplantation. The elevation 
under the graft over the trunk area was continu-
ously observed by means of optical coherence 
tomography throughout the follow-up period (Fig. 2 
of our article, and Fig. S11 in the Supplementary 
Appendix of our article; see also Fig. S1B in the 
Supplementary Appendix available with this letter). 
On the basis of fluorescein angiograms obtained 
during the first year and also at 22 months after 
transplantation, we concluded that there was no 
evidence of new exudative neovascularization in 
this area. On review of the optical coherence 
tomographic images, we agree that the results 
support the presence of a vessel structure under 
the transplanted iPSC-RPE sheet at 4 weeks after 
transplantation and thereafter (Fig. S1B in the 
Supplementary Appendix available with this let-
ter, and Fig. S11 in the Supplementary Appendix 
of our article). This structure could indicate the 
growth of new vessels or the reperfusion of exist-
ing, nonleaky vessels, a finding consistent with 
the interpretation by Souied et al. We do not in-
terpret the results obtained by means of indocya-
nine green angiography as supporting a change 
in vascular pattern (Fig. S1C in the Supplemen-
tary Appendix available with this letter).
Optical coherence tomographic angiography 
would disclose the presence of a vascular net-
work or nonexudative vasculature in more detail, 
but we could not obtain an informative image 
because of the unstable fixation of the eye. Sheets 
of iPSC-RPE cells secrete vascular endothelial 
growth factor from the basal surface, and the 
choroid seems to be relatively well maintained 
under and near the transplanted iPSC-RPE graft 
(Table S6 and Fig. S11 in the Supplementary 
Appendix of our article). At present, we cannot 
determine whether these vessels are benign or 
pathogenic.
Michiko Mandai, M.D., Ph.D.
RIKEN Center for Developmental Biology 
Kobe, Japan
Yasuo Kurimoto, M.D., Ph.D.
Institute of Biomedical Research and Innovation Hospital 
Kobe, Japan
Masayo Takahashi, M.D., Ph.D.
RIKEN Center for Developmental Biology 
Kobe, Japan 
retinalab@ cdb . riken . jp
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
DOI: 10.1056/NEJMc1706274
More on Co-Occurrence of COMT and BRCA1/2 Variants  
in a Population
To the Editor: Movassagh et al. (May 25 issue)1 
report an association between a synonymous 
variant (rs165631) in COMT and a reduced risk of 
cancer among female carriers of the mutation 
BRCA1 or BRCA2. The result was based on an 
analysis involving 25 patients with breast can-
cer who had germline BRCA1/2 alterations in the 
Cancer Genome Atlas and 15 presumably can-
cer-free women with BRCA1/2 nonsense and 
frameshift alterations in the Exome Sequencing 
Project of the National Heart, Lung, and Blood 
Institute (NHLBI). Given the potential for mis-
interpretation of the results, we feel obliged to 
correct the impression that rs165631 protects 
carriers of the BRCA1 or BRCA2 mutation from 
cancer.
On behalf of the Consortium of Investigators 
of Modifiers of BRCA1/2,2 we examined existing 
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data from 26,660 women with pathogenic vari-
ants of BRCA1 or BRCA2 and found no evidence 
of an association between rs165631 and the risk 
of either breast cancer or ovarian cancer among 
BRCA1/2 carriers (Table 1). The effect sizes for es-
tablished genetic modifiers of the risk of breast 
and ovarian cancer amongBRCA1/2 carriers are 
modest. Very large sample sizes are required to 
reliably identify associations between such mod-
ifiers and the relative risk of cancer.3
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To the Editor: Movassagh et al. report an asso-
ciation between the COMT variant rs165631 and a 
reduced risk of breast cancer among female car-
riers of a BRCA1/2 pathogenic variant. The result 
was reported to be based on an analysis involving 
40 carriers of truncating variants: 25 patients with 
breast cancer identified in the Cancer Genome 
Atlas and 15 women in the Exome Sequencing 
Project of the NHLBI who were assumed to be 
unaffected. The Supplementary Appendix provid-
ed with their letter (available at NEJM.org) indi-
cates that the analysis included carriers of mis-
sense variants. Most troubling, the data set included 
8 carriers of the common BRCA2 c.9976A→T 
(p.Lys3326Ter) variant associated with only a 
modest risk of breast or ovarian cancer (odds ra-
tio approximately 1.3 per allele),1 and four addi-
tional missense variants listed as benign in the 
BRCA Exchange. These 12 women are thus irrel-
evant to analyses of modifiers of the high-risk 
BRCA1/2 pathogenic variants used in clinical prac-
tice. These observations, and the fact that rs165631 
has not been revealed as a potential modifier in 
previous large-scale genomewide association stud-
ies involving BRCA1/2 carriers, indicate that it is 
premature to consider rs165631 as a potential 
modifier of cancer risk among such women.
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The author replies: Our decision to highlight 
the rs165631 variant was based on three coincid-
ing observations: overrepresentation in a subgroup 
of BRCA1/2 carriers selected from non–cancer-
related studies, its position in a gene (COMT) 
with high biologic relevance,1 and its synonymous 
nature in one of the very few genes in which syn-
onymous variants have been shown to affect the 
protein function.2 We computed overrepresenta-
tion using the minor allele frequency of rs165631, 
which was calculated on the basis of 60,418 per-
sons and ranged between 0 and 0.19, depending 
on ethnicity; the 25 patients with BRCA1/2 in the 
Cancer Genome Atlas were not included in any of 
our statistical analyses. We found the above coin-
cidence intriguing and reported it as a prelimi-
nary observation in our letter in order to allow 
for testing in larger data sets of BRCA1/2 carriers 
and perhaps in experimental settings. The over-
representation was not seen in an analysis involv-
ing the 26,660 carriers of the BRCA1/2 mutation, 
with and without cancer, that Chenevix-Trench 
et al. report. Therefore, unless different sup-
portive data are presented, observations regard-
ing rs165631 can be considered only as prelim-
inary.
Spurdle et al. comment on the size of our 
data set. We appreciate the high power of the 
large, BRCA1/2-positive data sets, such as the one 
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presented by Chenevix-Trench et al., for the pur-
pose of identifying risk modifiers, including 
those with modest effects. It is clear that the 
public population data sets do not support such 
high-powered design and have additional draw-
backs, such as the assumption of noncancer 
status, the limited nature of individual-level 
information, and of course the lower frequency 
of cancer-predisposing alleles. However, we be-
lieve that the population-based sets offer an alter-
native advantage in allowing searches for poten-
tial modifiers, functional variants, or both. In 
contrast with cancer-based data sets, which are 
often enriched in their inclusion of clinic-referred 
patients, family members, and persons using pre-
ventive measures owing to awareness of carrier 
status (all of which are taken into account by the 
prospective statistical approaches used), popula-
tion-based data sets are likely to be more repre-
sentative of participants who are unaware of their 
carrier status. In the current era of genetic aware-
ness, this factor alone could indicate the absence 
of family history or the presence of a weak family 
history and might (theoretically) suggest the pres-
ence of stronger modifiers. Our analysis shows 
that the NHLBI data set contains more than 
12,000 rare alleles classified in the Human Ge-
nome Mutation Database3 as causative of disease 
for 1 or more of 18 hereditary cancer-implicating 
syndromes with autosomal dominant inheritance. 
We believe that these data sets, when used with 
awareness of their limitations, are worth explor-
ing in the search for potential hereditary cancer-
preventive signatures.
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MEDICAL MUSICAL GROUP
The Medical Musical Group is seeking participants for its 
symphony orchestra and chorale. The group will perform a 
concert in Washington, DC, on Nov. 5. The concert will be fol-
lowed by a trip to Costa Rica (Nov. 6–12) and Nicaragua (Nov. 
12–16), featuring a performance in San Jose, Costa Rica, on 
Nov. 11.
Contact MMG, 1700 17th Street, NW, Suite 508, Washington, 
DC 20009; or call (202) 797-0700; or fax (202) 797-0771; or e-mail 
vanmmg@hotmail.com; or see http://www.medicalmusical 
.org.
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